Title
Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin.

Permalink
https://escholarship.org/uc/item/1pq5m49f

Journal
Journal of the American Chemical Society, 141(30)

ISSN
0002-7863

Authors
Callmann, Cassandra E
LeGuyader, Clare LM
Burton, Spencer T
et al.

Publication Date
2019-07-18

DOI
10.1021/jacs.9b04272

Peer reviewed
Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin

Cassandra E. Callmann,†,‡ Clare L. M. LeGuyader,† Spencer T. Burton,‡ Matthew P. Thompson,†∥ Robert Hennis,† Christopher Barback,§ Niel M. Henriksen,∥ Warren C. Chan,† Matt J. Jaremko,† Jin Yang,® Arnold Garcia,® Michael D. Burkart,© Michael K. Gilson,∥ Jeremiah D. Momper,∥ Paul A. Bertin,§ and Nathan C. Gianneschi*†

†Department of Chemistry & Biochemistry, University of California San Diego, La Jolla, California 92093, United States
‡Departments of Chemistry, Materials Science & Engineering, Biomedical Engineering, Chemistry of Life Processes Institute, International Institute for Nanotechnology, Simpson Querrey Institute, Northwestern University, Evanston, Illinois 60208, United States
§Department of Radiology, University of California San Diego, La Jolla, California 92093, United States
®Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
©Elevance Renewable Sciences, Inc. 2501 Davey Road, Woodridge, Illinois 60517, United States

ABSTRACT: We describe the design, synthesis, and antitumor activity of an 18 carbon Ω,Ω-dicarboxylic acid monoconjugated via an ester linkage to paclitaxel (PTX). This 1,18-octadecanedioic acid-PTX (ODDA-PTX) prodrug readily forms a noncovalent complex with human serum albumin (HSA). Preservation of the terminal carboxylic acid moiety on ODDA-PTX enables binding to HSA in the same manner as native long-chain fatty acids (LCFAs), within hydrophobic pockets, maintaining favorable electrostatic contacts between the ω-carboxylate of ODDA-PTX and positively charged amino acid residues of the protein. This carrier strategy for small molecule drugs is based on naturally evolved interactions that mimic the natural binding modes with HSA is a drug delivery strategy for cancer with potential in optimized dosing, stability, solubility, and efficacy by hitchhiking on these metabolic pathways. Binding interactions between HSA and LCFAs have been extensively studied, with as many as 7 moderate- to high-affinity binding pockets identified through nuclear magnetic resonance (NMR) and protein crystallography. In five of these sites, LCFA binding is stabilized through specific electrostatic interactions between the terminal LCFA carboxylate anion and positively charged amino acid residues at the base of otherwise hydrophobic binding pockets of HSA. These interactions are a consistent structural feature of thermodynamically stable, natural binding modes between LCFA and HSA. However, in classical drug lipidation strategies, this electrostatic interaction is extinguished when the single carboxylic acid of an LCFA is conjugated to the warhead, often via ester, amide, or hydrazone linkage. Indeed, the first and only example utilizing a long-chain fatty diacid, Ozempic (semaglutide), was approved by the FDA in 2017. Maintaining the naturally evolved LCFA carboxylate contact is a critical feature contributing to semaglutide’s performance as a once-weekly glucagon-like-peptide-1 receptor agonist for type-2 diabetes.

Herein, we employ an 18 carbon Ω,Ω-dicarboxylic acid as the HSA-binding motif of a prodrug conjugate. This conserves the high affinity electrostatic interactions between the ω-carboxylate and HSA, while maintaining the Ω-carboxylate for drug conjugation. This approach preserves the natural binding mode and mimics HSA engagement of natural LCFA (Figure 1). Specifically, 1,18-octadecanedioic acid (ODDA) was conjugated to paclitaxel (PTX) to produce a mono-

Received: April 19, 2019
Published: July 18, 2019
not exceed 15 mg/kg due to toxicity (see SI). Tumor growth for treatment. E response of 1-13C acid, showing its rapid displacement. Titrated into a pre-equilibrated solution of HSA with palmitic-acid binding pockets at concentrations lower than that of the native ligand, demonstrating a high binding affinity to HSA.

**Figure 1.** Design of ODDA-PTX and HSA binding. (a) Chemical structure of ODDA-PTX. (b) Modeling of ODDA-PTX binding to 7 LCFAs sites on HSA. (c) Molecular model of HSA with ODDA-PTX bound in native LCFAs site 4 (sphere). (d) NMR titration of ODDA-PTX into a pre-equilibrated, saturated solution of palmitic-1-13C acid (C16:0, 2.3 mM) with HSA (0.45 mM). ODDA-PTX displaces C16:0 in all observable fatty acid binding pockets at concentrations lower than that of the native ligand, demonstrating a high binding affinity to HSA.

Functionalized PTX ester at the 2′-hydroxyl (ODDA-PTX, Figure 1a, Figures S1 and S2). PTX is one of the most widely used chemotherapeutic agents. PTX promotes tubulin polymerization and arrests cell division, leading to apoptotic cell death.27 Functionalization of PTX at the 2′-hydroxyl prevents this mode of action.28 Indeed, an in vitro polymerization assay confirmed ODDA-PTX performed as a prodrug (Figure S3). Therefore, cytotoxic activity of ODDA-PTX is regained only when PTX is free from ODDA.

ODDA-PTX was mixed with HSA to yield a water-soluble complex at a 5:1 prodrug:protein mol ratio, designated VTX (Figure 1b,c. “V” = Roman numeral for five, signifying the number of equivalents of ODDA-PTX per HSA. “TX” = taxane). VTX was readily reconstituted in PBS following lyophilization, yielding a homogeneous solution. HSA binding sites for palmitic acid (C16:0) and other LCFAs are known;16,17 thus the interaction of ODDA-PTX with HSA was examined experimentally by NMR displacement studies18,19 with palmitic-1-13C acid (Figure 1d). ODDA-PTX was titrated into a pre-equilibrated solution of HSA with palmitic-1-13C acid, showing its rapid displacement.

To corroborate these data, VTX was modeled using molecular dynamics simulations (Figure 1b,c, Figures S4–S6, Table S1). It was determined that fatty acid binding sites 1, 2, 4, and 5 were the most likely binding locations for ODDA-PTX; modes consistent with native binding of LCFAs. Importantly, VTX preserves the tertiary structure and thermal stability of HSA as determined by circular dichroism spectroscopy (Figure S7). A rapid equilibrium dialysis assay showed that >95% of ODDA-PTX was bound to HSA down to 0.5 μM (Table S2), with isothermal titration calorimetry confirming multiple binding sites (Figure S8). Dynamic light scattering and cryogenic transmission electron microscopy revealed VTX as a fully dispersed prodrug:protein complex, similar to native HSA, not a nanoparticulate aggregate (Figure S9).

The cell-free stability of ODDA-PTX and VTX was assayed over a range of conditions by high performance liquid chromatography (Figures S10–S12). Cytotoxicity of VTX was assessed in vitro, confirming activity at nM concentrations with respect to PTX (Table S3). The metabolic stability and in vitro intrinsic clearance of ODDA-PTX was compared to PTX in human liver microsomes (Figure S13), demonstrating similar rates of metabolism. Significantly, blocking the fatty acid translocase/CD36 receptor, a key protein involved in uptake of LCFAs across cell membranes26 with implications in metastatic cancers,16,30 reduced the cytotoxicity of ODDA-PTX, but not PTX (Figure S14). This provides evidence that ODDA-PTX enters cells through different pathways from PTX, and importantly, through the same pathways as LCFAs.

VTX was evaluated as an antitumor agent in subcutaneous xenograft mouse models of human cancer. Therapeutic efficacy was determined by monitoring tumor growth and survival versus nontreated controls and compared to two FDA-approved paclitaxel formulations, Abraxane (nanoparticle albumin-bound PTX) and Cremophor-formulated PTX...
Initial studies were carried out in the HT-1080 human fibrosarcoma model, as it is predictable, fast-growing, and known to be taxane-responsive (Figure 2). The therapeutic index (TI) was defined as the ratio of maximum tolerated dose (MTD) to minimum effective dose (MED). Where MTD was the highest nonlethal deliverable dose and less than 20% weight loss, and MED was the lowest dose showing a delay in tumor growth relative to nontreated controls. Efficacy of VTX was investigated in the HT-1080 model following intravenous (IV) injection at 5, 60, 120, and 250 mg/kg with respect to PTX concentration every 7 days for 4 weeks (q/7dx4). Animals responded to VTX in a dose-dependent manner (Figure 2a). Complete tumor regression (5/8) or dramatically suppressed progression was observed in animals administered VTX at 250 mg/kg, with no evidence of drug-associated toxicity observed (Figure 2b, Figures S15 and S16). Conversely, animals administered Abraxane at 20 mg/kg with respect to PTX concentration experienced significant treatment-associated lethality (Figure S17). Therefore, the highest dose of Abraxane administered in this model was limited to 15 mg/kg. We note that these MTDs are lower than what is reported in several published studies. Similar antitumor activity of crPTX at 15 mg/kg was observed to that of Abraxane at 15 mg/kg (Figure 2c,d), the reported MTD of crPTX.

Elevated doses of VTX significantly extended survival time and inhibited tumor growth over nontreated controls (Figure 2b and Figure S18), whereas the improvement of survival time for Abraxane and crPTX was modest. The lowest administered dose (5 mg/kg) of VTX and Abraxane had similar effects on median survival time and both treatments sufficiently suppressed tumor growth relative to nontreated controls over the course of the study (p-value = 0.041 and 0.045, respectively, based on an unpaired t test where p < 0.05 was considered statistically significant). This was defined as the MED for both VTX and Abraxane in this model and with this dosing regimen (Figure S19). In evaluating the efficacy in tumor growth suppression and survival of animals treated with VTX and Abraxane, we conclude a distinct advantage of Abraxane over VTX at 250 mg/kg (Figures S20 and S21). Half-life and area under the plasma concentration versus time curve (AUC) of PTX in animals treated with VTX is higher than that of Abraxane, suggesting that VTX acts as a depot for the cytotoxin.

Biodistribution of VTX was studied at 250 mg/kg with respect to PTX content in HT-1080 xenografts in comparison to Abraxane and crPTX in both the tumor and the liver at 1, 4, and 24 h postinjection (Figure 3). The highest initial tumor concentration was in animals administered crPTX (Figure 3a). However, the tumor concentration of metabolite PTX in animals administered VTX steadily increased as a function of time, consistent with the depot-like PK data. Minimal accumulation in the liver was observed for VTX, compared to the high levels observed for both the nanoscale aggregates of Abraxane (see Figure S9) and crPTX at early time points (Figure 3b). It has been proposed that Cremophor imparts nanoparticle-like properties to the crPTX formulation with liver accumulation as a result.

Given the promising efficacy and tolerance (as measured by body weight) observed at 250 mg/kg with respect to PTX concentration, the toxicity of VTX at this dose in nu/nu mice was further evaluated following IV injection (q/7dx4) and compared to crPTX and Abraxane at 15 mg/kg. A complete blood count (CBC) panel and serum chemical analysis was obtained 24 h after the final injection (Table S4, Figures S22 and S23). Nearly all parameters were equivalent between all treatment groups, despite animals being administered VTX at a 16-fold higher dose of PTX than those administered Abraxane or crPTX (Figures S24 and S25).

Additional efficacy studies were completed in HT-29 (human colorectal adenocarcinoma) and Panc-1 (human pancreas ductal carcinoma) models, both known targets of taxane therapy (Figure 4). The trends in efficacy from the HT-1080 model were also observed in these models, where VTX at 250 mg/kg was well-tolerated and flat-lined tumor growth (Figure 4, Figure S26). Abraxane showed no significant therapeutic effect at 15 mg/kg in the Panc-1 model. Thus, we explored Abraxane at a higher dose (30 mg/kg) with 2/8 mice experiencing acute lethality (Figure S27). Conversely, 2 animals administered Abraxane at 20 mg/kg is similar to those administered VTX at 250 mg/kg (Figures S20 and S21). Half-life and area under the plasma concentration versus time curve (AUC) of PTX in animals treated with VTX is higher than that of Abraxane, suggesting that VTX acts as a depot for the cytotoxin.

Biodistribution of VTX was studied at 250 mg/kg with respect to PTX content in HT-1080 xenografts in comparison to Abraxane and crPTX in both the tumor and the liver at 1, 4, and 24 h postinjection (Figure 3). The highest initial tumor concentration was in animals administered crPTX (Figure 3a). However, the tumor concentration of metabolite PTX in animals administered VTX steadily increased as a function of time, consistent with the depot-like PK data. Minimal accumulation in the liver was observed for VTX, compared to the high levels observed for both the nanoscale aggregates of Abraxane (see Figure S9) and crPTX at early time points (Figure 3b). It has been proposed that Cremophor imparts nanoparticle-like properties to the crPTX formulation with liver accumulation as a result.

Given the promising efficacy and tolerance (as measured by body weight) observed at 250 mg/kg with respect to PTX concentration, the toxicity of VTX at this dose in nu/nu mice was further evaluated following IV injection (q/7dx4) and compared to crPTX and Abraxane at 15 mg/kg. A complete blood count (CBC) panel and serum chemical analysis was obtained 24 h after the final injection (Table S4, Figures S22 and S23). Nearly all parameters were equivalent between all treatment groups, despite animals being administered VTX at a 16-fold higher dose of PTX than those administered Abraxane or crPTX (Figures S24 and S25).

Additional efficacy studies were completed in HT-29 (human colorectal adenocarcinoma) and Panc-1 (human pancreas ductal carcinoma) models, both known targets of taxane therapy (Figure 4). The trends in efficacy from the HT-1080 model were also observed in these models, where VTX at 250 mg/kg was well-tolerated and flat-lined tumor growth (Figure 4, Figure S26). Abraxane showed no significant therapeutic effect at 15 mg/kg in the Panc-1 model. Thus, we explored Abraxane at a higher dose (30 mg/kg) with 2/8 mice experiencing acute lethality (Figure S27). Conversely, 2...
animals experienced complete tumor regression upon administration of high doses of VTX.

In conclusion, we have developed a carrier system for albumin-mediated delivery of PTX. The design strategy is based on mimicking the natural interaction between HSA and LCFAs, by monofunctionalizing ODDA with PTX. We have demonstrated efficacy of VTX in three xenograft models: HT-1080 (fibrosarcoma), PANC-1 (pancreatic cancer), and HT-29 (colon cancer). The overall survival of animals is significantly extended when administered VTX, compared to clinical formulations. The PK profile of VTX differs significantly from Abraxane, as does the biodistribution compared to Abraxane and crPTX. Given the relationship between HSA, fatty acids, and the tumor microenvironment, this is a potential strategy for drug delivery to cancers that have increased demands for HSA and fatty acids. This may be of importance in cancers that demonstrate multidrug resistance, where conventional PTX treatment is ineffective. We propose this strategy as a generalizable new route for the facile modification of drugs for engaging HSA without the need for complex nanoscale formulations or covalent modification of the protein.

ASSOCIATED CONTENT

* Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.9b04272.
Synthetic schemes, statistical analyses, methods, molecular dynamics simulations details (PDF)
Amber files (ZIP)

AUTHOR INFORMATION

Corresponding Author
*nathan.gianneschi@northwestern.edu

Orcid
Niel M. Henriksen: 0000-0002-7916-0757
Michael D. Burkart: 0000-0002-4472-2254
Michael K. Gibson: 0000-0002-3375-1738
Nathan C. Gianneschi: 0000-0001-9945-5475

Notes
The authors declare the following competing financial interest(s): N.C.G. acknowledges a conflict of interest as a founder and shareholder of Vybyl Biopharma, Inc., a licensee of related technologies. M.K.G. has an equity interest in and is a cofounder and scientific advisor of VeraChem LLC.

ACKNOWLEDGMENTS

Research was conducted with support from Elevance Renewable Sciences. C.E.C. thanks both the ARCS Foundation and the Inamori Foundation for fellowship support. W.C.C. and M.J.J. were supported by NIH/NCI T32 CA09523. The authors thank Dr. Yongxuan Su and the UC San Diego Mass Spectrometry Facility for assistance with LC/MS. The authors also thank Dr. Irawati Kendala and the Developmental Therapeutics Core at Northwestern University, as well as Dr. Jianjun Wei at Northwestern University, for assistance with toxicity and pathology analyses.

REFERENCES

(1) Hoogenboezem, E. N.; Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 2018, 130, 73−89.
(2) Elsaid, B.; Kratz, F. Impact of albumin on drug delivery—new applications on the horizon. J. Controlled Release 2012, 157 (1), 4−28.
(3) Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D.; Noker, P.; Yao, R.; Labao, E.; Hawkins, M.; Soon-Shiong, P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12 (4), 1317−24.
(4) Shan, L.; Zhuo, X.; Zhang, F.; Dai, Y.; Zhu, G.; Yung, B. C.; Fan, W.; Zhai, J.; Jacobson, O.; Kiesewetter, D. O.; Ma, Y.; Yao, G.; Chen, X. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy. Theranostics 2018, 8 (7), 2018−2030.
(5) Kragh-Hansen, U. Structure and ligand binding properties of human serum albumin. Danish Med. Bull. 1990, 37 (1), 57−84.
(6) Ghuman, J.; Zunzain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 2005, 353 (1), 38−52.
(7) van der Vusse, G. J. Albumin as fatty acid transporter. Drug Metab. Pharmacokinet. 2009, 24 (4), 300−7.
(8) Michalopoulos, E.; Bulusu, V.; Kamphorst, J. J. Metabolic scavenging by cancer cells: when the going gets tough, the tough keep eating. Br. J. Cancer 2016, 115, 635.
(9) Merlot, A. M.; Kalinowski, D. S.; Richardson, D. R. Unraveling the mysteries of serum albumin—more than just a serum protein. Front. Physiol. 2014, 5, 299.
(10) White, E. Exploiting the bad eating habits of Ras-driven cancers. Genes Dev. 2013, 27 (19), 2065−2071.
(11) Comisson, C.; Davidson, S. M.; Soydaner-Azeloglu, R. G.; Parker, S. J.; Kamphorst, J. J.; Hackett, S.; Grabocka, E.; Nofal, M.; Drebin, J. A.; Thompson, C. B.; Rabinowitz, J. D.; Metallo, C. M.; S.; Vander Heiden, M. G.; Bar-Sagi, D. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497, 633.
(12) Carracedo, A.; Cantley, L. C.; Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 2013, 13 (4), 227−32.
(13) Hirschey, M. D.; DeBerardinis, R. J.; Diehl, A. M. E.; Drew, J. E.; Frezza, C.; Green, M. F.; Jones, L. W.; Ko, Y. H.; Le, A.; Lea, M. A.; Locasale, J. W.; Longo, V. D.; Lyssiotis, C. A.; McDonnell, E.; Mehrmohamadi, M.; Michelotti, G.; Muralidhar, V.; Murphy, M. P.; Pedersen, P. L.; Poore, B.; Raffaghello, L.; Rathmell, J. C.; Sivanand, S.; Vander Heiden, M. G.; Wellen, K. E. Dysregulated metabolism contributes to oncogenesis. Sem. Cancer Biol. 2015, 35, S129−S150.
(14) Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 2009, 324 (5930), 1029−1033.
(15) Pascual, G.; Argüinimova, A.; Mojette, S.; Martín, M.; Castellanos, A.; Attolini, C. S.−O.; Berenguer, A.; Prats, N.; Toll, A.; Hueto, J. A.; Bescós, C.; Di Croce, L.; Beníat, S. A. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 2017, 541, 41.
(16) Curry, S.; Brick, P.; Franks, N. P. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 1999, 1441 (2–3), 131–40.
(17) Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 1998, 5 (9), 827–35.
(18) Simard, J. R.; Zunszain, P. A.; Ha, C. E.; Yang, J. S.; Bhagaran, N. V.; Petipas, I.; Curry, S.; Hamilton, J. A. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (50), 17958–17963.
(19) Simard, J. R.; Zunszain, P. A.; Hamilton, J. A.; Curry, S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol. 2006, 361 (2), 336–51.
(20) Bradley, M. O.; Swindell, C. S.; Anthony, F. H.; Wittrn, P. A.; Devanesan, P.; Webb, N. L.; Baker, S. D.; Wolf, A. C.; Donehower, R. C. Tumor targeting by conjugation of DHA to paclitaxel. J. Controlled Release 2001, 74 (1), 233–236.
(21) Spector, A. A.; John, K.; Fletcher, J. E. Binding of long-chain fatty acids to bovine serum albumin. J. Lipid Res. 1969, 10 (1), 56–67.
(22) Irby, D. J.; Du, C.; Li, F. Lipid–Drug Conjugate for Enhancing Drug Delivery. Mol. Pharmacol. 2017, 14 (5), 1325–1338.
(23) Sarett, S. M.; Werfel, T. A.; Lee, L.; Jackson, M. A.; Kilchrist, K. V.; Brantley-Sieders, D.; Duvall, C. L. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc. Natl. Acad. Sci. U. S. A. 2017, 114 (32), E6490–E6497.
(24) Liu, H.; Moynihan, K. D.; Zheng, Y.; Szteto, G. L.; Li, A. V.; Huang, B.; Van Egeren, D. S.; Park, C.; Irvine, D. J. Structure-based Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties. J. Med. Chem. 2016, 59 (7), 3730–3740.
(25) Liang, Y.; Han, H.; Liu, L.; Duan, Y.; Yang, X.; Ma, C.; Zhu, Y.; Han, J.; Li, X.; Chen, Y. CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells. Oncogene 2018, 7 (12), 98.
(26) Bonen, A.; Campbell, S. E.; Benton, C. R.; Chabowski, A.; Coort, S. L. M.; Han, X.-I.; Koonen, D. P. Y.; Glatz, J. F. C.; Luiken, J. J. F. P. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc. Natl. Acad. Sci. 2004, 101 (2), 245–249.
(27) Wang, T.-H.; Wang, H.-S.; Soong, Y.-K. Paclitaxel-induced cell death. Cancer 2000, 88 (11), 2619–2628.
(28) Sharma, S.; Lagisetti, C.; Poliks, B.; Coates, R. M.; Kingston, D. G. J.; Bane, S. Dissecting the Paclitaxel-Microtubule Association: Quantitative Assessment of the 2′-OH Group. Biochemistry 2013, 52 (13), 2328–2336.
(29) Connett, J. M.; Buettner, T. L.; Anderson, C. J. Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody IA3 in a colon cancer model. Clin. Cancer Res. 1999, 5 (10 Suppl), 3207s–3212s.
(30) Mach, C. M.; Mathew, L.; Mosley, S. A.; Kurzrock, R.; Smith, J. A. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res. 2009, 29 (6), 1895–1899.
(31) Desai, N. P.; Trieu, V.; Hwang, L. Y.; Wu, R.; Soon-Shiong, P.; Gradishar, W. J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Drugs 2008, 19 (9), 899–909.
(32) Miele, E.; Spinelli, G. P.; Tomao, F.; Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4, 99–105.
(33) Zhao, M.; Lei, C.; Yang, Y.; Bu, X.; Ma, H.; Hong, H.; Liu, J.; Fang, X.; Hu, Z.; Fang, Q. Abxnavox, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. PLoS One 2015, 10 (7), e0131429.
(34) Huang, G. S.; Lopez-Barcons, L.; Freeze, B. S.; Smith, A. B.; Goldberg, G. L.; Horwitz, S. B.; McDaid, H. M. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. Clin. Cancer Res. 2006, 12 (1), 298–304.
(35) Gabrielsson, J.; Weiner, D. Non-compartmental analysis. Methods Mol. Biol. (N. Y., NY, U. S.) 2012, 929, 377–89.
(36) Gellerblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Combined drug EL: the drawbacks and the advantages for drug formulation. Eur. J. Cancer 2001, 37 (13), 1590–8.
(37) Chioarean, E. G.; Von Hoff, D. D. Taxanes: impact on pancreatic cancer. Anti-Cancer Drugs 2014, 25 (5), 842–9.
(38) Kamphorst, J. J.; Nofal, M.; Commissio, C.; Hackett, S. R.; Lu, W.; Grabbeck, E.; Vander Heiden, M. G.; Miller, G.; Drebin, J. A.; Bar-Sagi, D.; Thompson, C. B.; Rabinowitz, J. D. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015, 75 (3), 544–53.
(39) Liu, Q.; Luo, Q.; Halim, A.; Song, G. Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer. Cancer Lett. 2017, 401, 39–45.
(40) Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48.
(41) Podolski-Renić, A.; Andelkovich, T.; Banković, J.; Tanić, N.; Rudićić, S.; Pešić, M. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomed. Pharmacother. 2011, 65 (5), 345–353.
(42) Kratz, F.; Wannecke, A.; Scheuermann, K.; Stockmar, C.; Schwab, J.; Lazar, P.; Druecke, P.; Esser, N.; Dreux, J.; Bognan, D.; Bissantz, C.; Hinderling, C.; Folkers, G.; Fichtner, I.; Unger, C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. 2002, 45 (25), 5523–33.